company background image
IRMD logo

IRADIMED NasdaqGM:IRMD Stock Report

Last Price

US$54.21

Market Cap

US$687.0m

7D

2.3%

1Y

16.0%

Updated

24 Dec, 2024

Data

Company Financials +

IRADIMED CORPORATION

NasdaqGM:IRMD Stock Report

Market Cap: US$687.0m

IRMD Stock Overview

Develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. More details

IRMD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance5/6
Financial Health6/6
Dividends3/6

Rewards

Trading at 45.8% below our estimate of its fair value

Earnings are forecast to grow 15.5% per year

Earnings grew by 14.1% over the past year

Risk Analysis

Significant insider selling over the past 3 months

Unstable dividend track record


My Notes

Capture your thoughts, links and company narrative

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
Analyst Price Target
Consensus Narrative from 2 Analysts

Expansion And New MRI-Compatible Pump Set To Strengthen Future Earnings Stability

Key Takeaways Strategic moves to expand production capacity and modify sales plans aim to stabilize revenue and capitalize on new product demand. Robust cash flow from improved working capital management supports future growth initiatives and earnings stability.
View narrative
US$60.00
FV
9.6% undervalued intrinsic discount
14.67%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
6 days ago author updated this narrative

IRADIMED CORPORATION Competitors

Semler Scientific

NasdaqCM:SMLR

US$590.8m

Tactile Systems Technology

NasdaqGM:TCMD

US$415.9m

Zynex

NasdaqGS:ZYXI

US$257.0m

InMode

NasdaqGS:INMD

US$1.4b

Price History & Performance

Summary of share price highs, lows and changes for IRADIMED
Historical stock prices
Current Share PriceUS$54.21
52 Week HighUS$57.95
52 Week LowUS$40.18
Beta0.83
1 Month Change1.84%
3 Month Change9.78%
1 Year Change15.98%
3 Year Change14.17%
5 Year Change131.86%
Change since IPO447.58%

Recent News & Updates

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Recent updates

IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

Aug 08
IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17
Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13
IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05
At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12
Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Shareholder Returns

IRMDUS Medical EquipmentUS Market
7D2.3%-1.1%-2.2%
1Y16.0%10.1%23.9%

Return vs Industry: IRMD exceeded the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: IRMD underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is IRMD's price volatile compared to industry and market?
IRMD volatility
IRMD Average Weekly Movement4.6%
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: IRMD has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: IRMD's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992148Roger Susiwww.iradimed.com

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.

IRADIMED CORPORATION Fundamentals Summary

How do IRADIMED's earnings and revenue compare to its market cap?
IRMD fundamental statistics
Market capUS$687.03m
Earnings (TTM)US$18.63m
Revenue (TTM)US$71.31m

36.9x

P/E Ratio

9.6x

P/S Ratio

Is IRMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IRMD income statement (TTM)
RevenueUS$71.31m
Cost of RevenueUS$16.30m
Gross ProfitUS$55.00m
Other ExpensesUS$36.38m
EarningsUS$18.63m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.47
Gross Margin77.14%
Net Profit Margin26.12%
Debt/Equity Ratio0%

How did IRMD perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

31%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 22:14
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IRADIMED CORPORATION is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lawrence SolowCJS Securities, Inc.
Frank TakkinenLake Street Capital Markets, LLC
Scott HenryRoth MKM